Automated radiosynthesis of [18F]DPA-714 on a commercially available IBA Synthera®.

The goal of this work was to develop a reliable method to produce the well-validated microglial activation PET tracer, [18F]DPA-714, routinely for clinical and preclinical research using an IBA Synthera®. Optimization of literature methods included reduced precursor mass and use of TBA HCO 3 as the phase transfer agent in place of Kryptofix® 222 in a 65-min synthesis with an average activity yield of 24.6 ± 3.8% (n = 5). Successful quality control testing and process validation results are reported. • An IND-approved method for production of [18F]DPA-714 on an IBA Synthera® is reported. • Reduction of precursor mass and replacement of Kryptofix® 222 as phase transfer agent support production of tracer in reliable quantities for clinical research. • Justification of 5% injected ethanol in pediatric PET tracer preparations was outlined. [ABSTRACT FROM AUTHOR]